Hjem › Leukæmi › Massachusetts
Leukæmi kliniske forsøg i Massachusetts
28 studier for Leukæmi søger deltagere på steder i Massachusetts.
Byer i Massachusetts
Officiel studietekst (engelsk)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT04996875Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
- Dana-Farber Cancer Institute, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Boston
RekruttererFase 3
Alder 18 til 18 · Alle køn · Opdateret 8. sep. 2026 · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Massachusetts General Hospital, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT07249346CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 til 90 · Alle køn · Opdateret 26. aug. 2026 · NCT07439211Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06001788ALL Backbone in AYAs
- Dana Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 til 51 · Alle køn · Opdateret 17. aug. 2026 · NCT07227584Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
- Mass General Brigham Cancer Institute, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 27. jul. 2026 · NCT07671209Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- Dana-Farber Cancer Institute, Boston
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 16. jul. 2026 · NCT06469307Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 19 til 110 · Alle køn · Opdateret 29. jun. 2026 · NCT02012699A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 12 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT04024761Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT06138587A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT05475925A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. maj 2026 · NCT03219450Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 18. maj 2026 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 30. apr. 2026 · NCT04256317Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 21. apr. 2026 · NCT05646576Shwachman Diamond Syndrome Registry and Study
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 6. apr. 2026 · NCT06056908Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 25. mar. 2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. feb. 2026 · NCT06644183A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 5. feb. 2026 · NCT07148180Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 15. dec. 2025 · NCT07052695SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT05842603HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2025 · NCT06487247Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.